Search
Displaying 251–260 of 1063 results
-
Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Disease
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive vision loss.
-
Why Bob and Lupe Reintsma are Supporting the Foundation Fighting Blindness
Beacon StoriesBob Reintsma has been passionate about finding cures for inherited retinal diseases for most of his life. Now, he and his wife, Lupe, want to make sure the work continues long after they’re gone. And they’re doing it in partnership with Foundation Fighting Blindness.
-
Dan Day - Making a Difference Now and for Future Generations
Beacon Stories“Because I have seen such tremendous progress over the years, and I want that progress to continue until the day when we have cures for all retinal diseases, it is important to me that the Foundation be part of my lasting legacy.”
-
Beacon Stories
“My husband and I have not been able to be significant Foundation supporters during our lifetimes,” she said, “but I would be honored to leave this gift as part of my legacy.”
-
Beyond Labels: The Inspiring Journey of a Refsum Disease Advocate
Beacon StoriesAfter years of seeking answers, Alan Gunzburg was formally diagnosed with Refsum disease, a rare genetic disorder. Drawing on his unique journey, Alan sheds light on the obstacles he’s faced and how his experience motivated him to make a positive impact in the lives of others.
-
Eye on the Cure Podcast | Episode 48: Jami Kern, PhD
Eye on the CureJune 16, 2023. Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company’s emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard
Beacon StoriesDr. Léveillard helped discover and develop a gene-agnostic, cone-preserving therapy for retinitis pigmentosa that’s moving into a clinical trial.
-
Breaking Barriers as an Attorney With Usher Syndrome
Beacon StoriesTara is a woman of extraordinary talents. A beloved twin sister, mother of two, and wife of 10 years, Tara leads a fulfilling life dedicated to advocating for others through law.
%20(7).png)
